



945505.0019

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Robert H. Zimmer

Serial No.: 10/050,903

Filed: January 16, 2002

)  
)  
)  
)  
)  
)

Examiner:

Group Art Unit: 1614

Confirmation No. 5841

RECEIVED  
JUN 20 2003  
TECH CENTER 1600/2900

For: Compositions and Methods For Enhanced Pharmacological Activity Through  
Oral and Parenteral Administration of Compositions Comprising Polypeptide  
Drug Substances and Other Poorly Absorbed Active Ingredients

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§1.56 and 1.97, the material listed on the attached form PTO-1449 is being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The references listed were cited in the International Search Report of the corresponding PCT application.

The enclosed references are being submitted pursuant to 37 C.F.R. §1.97(b)(3) before the first action on the merits. The references submitted with this Information Disclosure Statement were cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Serial No. 10/050,903

Attorney Docket No. 945505.0019

It is respectfully requested that the Examiner indicate consideration of the cited reference by returning a copy of the attached form PTO-1449 with initials or other appropriate marks.

Respectfully submitted,

Date: June 16, 2003



Basam E. Nabulsi  
Reg. No. 31,645  
Attorney for Applicants

CUMMINGS & LOCKWOOD  
Four Stamford Plaza  
P.O. Box 120  
Stamford, CT 06904-0120  
(203) 351-4321


I hereby certify that the enclosed Information Disclosure Statement, a PTO-1449 Form and cited references are being deposited with the United States Postal Service as first class mail, postage prepaid, addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 16, 2003.

Dated: June 16, 2003

  
Joan Simmons


.StmLib1:1018325.1 06/13/03

Form PTO-1449 (modified 2/91)	U.S. DEPT OF COMMERCE Patent and Trademark Office	Attorney Docket Number: 945505.0019	Serial No.: 10/050,903
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		Applicants:  Robert H. Zimmer	
		Filing date: 1/16/02	Group Art Unit: 1614



## U.S. PATENT DOCUMENTS

Examiner Initial	Patent number	Date	Inventor	Class	Sub class	Filing date if appropriate



## FOREIGN PATENT DOCUMENTS

Document number	Date	Country	Class	Sub class	Translation Yes	Translation No
WO 98/11126	3/19/1998	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Fukushima, K., Hypoglycemic Effect and Enhanced Gastrointestinal Absorption of Insulin Using New Cinnamoyl-phenylalanine Derivatives, Hokkaido Journal of Medical Science, Vol. 71, No. 6, 1996, pp. 727-743.
	Vergnolle, N, et al., Proteinase-Activated Receptor 2 (PAR <sub>2</sub> )-Activating Peptides: Identification of a Receptor Distinct From PAR <sub>2</sub> That Regulates Intestinal, Transport, Proceedings of the National Academy of Sciences of USA, National Academy of Science, Vol. 95, June 1998 (1998-06), pp. 7766-7771.
	Langguth, P., et al., The Challenge of Proteolytic Enzymes in Intestinal Peptide Delivery, Journal of Controlled Release, Elsevier Science Publishers B.V. Amsterdam, NL, Vol. 46, No. 1, May 1997, pp. 39-57.
	Egleton, R. D., et al., Improved Bioavailability to the Brain of Glycosylated Met-Enkephalin Analogs, Brain Research, Vol. 881, No. 1, 2000, pp. 37-46.
	Pauletti, G. M., et al., Improvement of Oral Peptide Bioavailability: Peptidomimetics and Prodrug Strategies, Advanced Drug Delivery Review, Vol. 27, No. 2-3, 1997, pp. 235-256.

Examiner:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	